| 摘要 |
The invention relates to monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for the treatment or prevention of muscle wasting, frailty, age-related sarcopenia, disuse atrophy and cachexia. |
